The US pharmaceutical market's 2009 value of will have increased by 2010. The growth is slightly higher growth than that predicted by most analysts, with many believing the market would contract over 2009-2010 for the first time in 50 years. The outperformance of market expectations in spite of wider economic restraints has been due to an increase in prices and higher purchasing sensitivity on the on the part of retail pharmacy chains leading to better inventory management. Manufacturers' attempts to expand access to and knowledge of public programmes to assist patients, as well as their co-payment of subsidies have also helped sustain market growth throughout the downturn. Of these factors, the most significant factor is the pricing flexibility that has helped sustain revenues. Analyst Robert J. Easton remarked that the 2010 healthcare reforms will re

strain pricing increases, but added ‘in the mean time...the industry has continued to raise prices in a very, very substantial rate...and they're going to keep doing it as long as they can.' Those techniques will keep the industry growing through 2011. By 2012-2013, increased rebate payments and controls on pricing will begin to erode the growth rates of the industry. However in 2014 the measures set out in the 2010 health care reform will begin to take effect, with coverage widening.

In Europe, Plavix's sales have been undermined by the launch of a generic clopidogrel bisulphate by the Swiss company Acino. US law proved more favourable, adjudging that Plavix's patents cover all versions of the clopidogrel isomer, not solely the bisulphate salt. A June 2010 legal victory delayed the US release of Apotex's generic clopidogrel until November 2011. As well as fighting generic competition in the EU, the two companies have sought to expand Plavix's indications, with a Phase III trial of the drug in paediatric patients underway in 2009. They have also filed for EU and US approval of Plavix for preventing major vascular events in patients suffering from atrial fibrillation. Plans for use of Plavix in a combination product with irbesartan and simvastatin were abandoned due to unpromising trial results, reports indicate.

Do you want to know the effects of the Obama government's legislation for US healthcare? Insurance coverage will be extended, expanding the pharma market. But at what price to the pharmaceutical industry in rebates and other costs? Will the healthcare reforms underwrite another decade of growth in the US pharma market, or has it reached its limits?

US Pharmaceutical Market Outlook 2011-2021 answers those questions with a deep, wide-ranging survey of the market. Our report analyses the leading therapeutic categories in the US market. We assess which areas have the strongest potential for growth and the most-promising R&D pipelines. You will also find out which areas are most threatened with contraction as patent expiries occur. Order today, staying ahead.

We provide forecasts and discussions for the top drugs in the US market. We profile the US market's leading players, with analyses of their growth strategies. Our report covers their plans to expand and diversify their portfolios, restructure their operations and consolidate positions in emerging markets. We provide revenue forecasts for the top companies in the US market and worldwide, putting the US market in context.

Our new report also provides analyses of the US generic drug market and the US OTC pharma market, studying the market drivers and restraints. We provide forecasts for those markets, and for leading companies in those rising sectors.

This report contains interviews with experts on prospects for the US market this decade, discussing matters such as:

• FDA funding and regulatory transparency
• The biosimilars market in light of the 2010 healthcare reforms
• The erosion of industry leadership to Europe
• The pressure on pricing within the US health insurance industry
• The legal and political complexities of the US pharma market this decade.

US Pharmaceutical Market Outlook 2011-2021 critically examines the world's most important pharma market. You will find sales forecasts, market share analyses, discussions of products and analyses of commercial drivers and restraints. We include 120 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today, benefiting your analyses and commercial ideas. US Pharmaceutical Market Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive a detailed analysis of prospects for the US market's growth from 2011 to 2021, including forecasts for main therapeutic categories, and those for the generic and OTC sectors
• You will find out how companies are performing in the US market, with forecasts and discussions for the leading companies overall, and for leading generics and OTC companies
• You will learn prospects for the leading products in the US pharma market, with US revenue forecasts for top brands
• You will discover the legal, regulatory and economic drivers and restraints operating in the US pharma market, especially implications of the 2010 healthcare reforms
• You will identify the key industry trends in this market, seeing opportunities and market requirements
• You will read expert opinion from our survey, including full interview transcripts.

How will the US pharma market develop, and which companies and products will be best placed to benefit from legal, regulatory and economic changes? This report gives you the trends and answers you need.